Rarely mentioned in the recent chaos in the markets is the biotech sector. With a heavy emphasis in 2020 and 2021 on finding cures and treatments for COVID-19, major drug approvals from the FDA have been few and far between this year.
In addition, with the recent emphasis and value on companies that actually make money instead of burn through it, there is yet another reason this sector has been ignored. While biotech companies usually move off drug announcements, they can move off an earnings report.
